{"schema_version":"secwatch.filing_event.v1","accession":"0001655759-24-000002","form_type":"8-K","ticker":"ARVN","cik":"0001655759","company_name":"ARVINAS, INC.","filed_at":"2024-01-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.996747+00:00","generated_at":"2026-06-07T02:22:09.996877+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Arvinas gets FDA/EMA clearance for ARV-393 and ARV-102; Phase 1 trials planned H1 2024","bullets":["FDA authorized IND for ARV-393, a PROTAC BCL6 degrader.","EMA authorized CTA for ARV-102, a PROTAC LRRK2 degrader.","Both first-in-human Phase 1 trials expected to start in H1 2024.","ARV-393 targets BCL6 protein; ARV-102 targets LRRK2 protein."],"urls":{"canonical":"https://secwatch.observer/filing/0001655759-24-000002","json":"https://secwatch.observer/filing/0001655759-24-000002.json","markdown":"https://secwatch.observer/filing/0001655759-24-000002.md","text":"https://secwatch.observer/filing/0001655759-24-000002.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000002/0001655759-24-000002-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1655759/000165575924000002/arvn-20240107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T02:22:09.996877+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}